Atria Investments Inc Purchases 15,296 Shares of CalciMedica, Inc. (NASDAQ:CALC)

Atria Investments Inc increased its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of CalciMedica in a report on Thursday, November 14th.

CalciMedica Stock Performance

CALC stock opened at $3.45 on Monday. CalciMedica, Inc. has a 1-year low of $2.68 and a 1-year high of $8.38. The stock’s fifty day simple moving average is $3.94 and its two-hundred day simple moving average is $4.44. The stock has a market cap of $46.51 million, a P/E ratio of -3.19 and a beta of 1.30.

Insider Activity

In related news, insider Eric W. Roberts acquired 53,333 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $199,998.75. Following the purchase, the insider now owns 164,706 shares in the company, valued at $617,647.50. This trade represents a 47.89 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Fred A. Middleton acquired 87,744 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $329,040.00. Following the completion of the purchase, the director now owns 814,300 shares in the company, valued at $3,053,625. This trade represents a 12.08 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 248,944 shares of company stock valued at $933,980 in the last 90 days. Insiders own 41.55% of the company’s stock.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.